利比里亚两轮2型新型口服脊髓灰质炎疫苗运动后脊髓灰质炎病毒抗体:一项整群、基于人群的血清流行率调查
2021年利比里亚发生2型循环疫苗衍生脊髓灰质炎病毒(cVDPV2)疫情后开展了两轮2型新型口服脊髓灰质炎疫苗(nOPV2)接种运动,本研究在第二轮接种4周后对0-59月龄儿童进行整群横断面血清流行率调查,发现2型脊髓灰质炎病毒血清流行率为38.3%(95%CI 33.7-43.0),报告接种两剂nOPV2的6月龄及以上儿童中2型血清流行率为42.1%,与接种一剂或未接种者无显著差异(p=0.39)。
要点
- 报告接种两剂nOPV2的6月龄及以上儿童中2型脊髓灰质炎病毒血清流行率为42.1%(95%CI 36.8-47.5)。
- 2型血清流行率在报告接种两剂、一剂和未接种儿童间无显著差异(p=0.39)。
- 1型和3型脊髓灰质炎病毒血清流行率分别为59.6%和53.0%。
核心结论
- 数据显示报告接种两剂nOPV2后2型脊髓灰质炎病毒血清流行率出乎意料地低。
- 该发现可能受资源有限地区既往已证实口服脊髓灰质炎疫苗免疫原性较低、儿童慢性肠道感染高流行及其他本文讨论因素的影响。
- 本研究结果提供了非洲地区疫情应对中nOPV2性能的首次评估。
研究设计与样本
- 本研究为整群、横断面、基于人群的血清流行率调查,在利比里亚四个地理区域采用整群抽样方法,随后对家庭进行简单随机抽样,每户随机选取一名符合条件的儿童。
- 调查对象为0-59月龄儿童,在第二轮nOPV2接种运动后超过4周开展。
- 采集干血斑标本并记录疫苗接种史,使用标准微量中和试验检测针对所有三种脊髓灰质炎病毒血清型的抗体滴度,检测在美国佐治亚州亚特兰大市美国疾病控制与预防中心完成。
- 500名入组参与者中436名(87%)获得可分析数据。
主要发现
- 436名可分析参与者中,371名(85%)经家长回忆报告接种两剂nOPV2,43名(10%)接种一剂,22名(5%)未接种。
- 针对2型脊髓灰质炎病毒的血清流行率为38.3%(95%CI 33.7-43.0;436名参与者中167名)。
- 6月龄及以上儿童中,报告接种两剂nOPV2者2型血清流行率为42.1%(95%CI 36.8-47.5;342名中144名),接种一剂者为28.0%(95%CI 12.1-49.4;25名中7名),未接种者为37.5%(95%CI 8.5-75.5;8名中3名),组间无显著差异(p=0.39)。
- 针对1型脊髓灰质炎病毒的血清流行率为59.6%(95%CI 54.9-64.3;436名中260名),针对3型为53.0%(95%CI 48.2-57.7;436名中231名)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel oral poliovirus vaccine type 2 (nOPV2) was administered in Liberia in response to an outbreak of circulating vaccine-derived poliovirus type 2 (cVDPV2) in 2021. We conducted a serological survey of polio antibodies after two national campaigns with nOPV2. METHODS: This clustered, cross-sectional, population-based seroprevalence survey was conducted in children aged 0-59 months, more than 4 weeks after the second nOPV2 vaccination round. We used a clustered sampling method in four geographical regions of Liberia, followed by a simple random sampling of households. One eligible child was randomly selected per household. Dried blood spot specimens were taken and vaccination history was recorded. The antibody titres against all three poliovirus serotypes were assessed using standard microneutralisation assays done at the US Centers for Disease Control and Prevention in Atlanta, GA, USA. FINDINGS: Analysable data were obtained from 436 (87%) of 500 enrolled participants. Of these, 371 (85%) children were reported via parental recall to have received two nOPV2 doses, 43 (10%) received one dose, and 22 (5%) received no doses. The seroprevalence against type 2 poliovirus was 38·3% (95% CI 33·7-43·0; 167 of 436 participants). No significant difference was observed between type 2 seroprevalence in children aged 6 months or older who were reported to have received two doses of nOPV2 (42·1%, 95% CI 36·8-47·5; 144 of 342), one dose (28·0%, 12·1-49·4; seven of 25), or no doses (37·5%, 8·5-75·5; three of eight; p=0·39). The seroprevalence against type 1 was 59·6% (54·9-64·3; 260 of 436), and the seroprevalence against type 3 was 53·0% (48·2-57·7; 231 of 436). INTERPRETATION: Unexpectedly, the data showed low type 2 seroprevalence after two reported doses of nOPV2. This finding is probably affected by the lower oral poliovirus vaccine immunogenicity previously demonstrated in resource-limited settings, with high prevalence of chronic intestinal infections in children and other factors discussed herein. Our results provide the first assessment of nOPV2 performance in outbreak response in the African region. FUNDING: WHO and Rotary International.
引用
- Kennedy SB, Macklin GR, Mason Ross G, et al. Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey. Lancet Glob Health. 2023. PMID: 37202026. doi:10.1016/S2214-109X(23)00116-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。